1
|
Heise V, Offer A, Whiteley W, Mackay CE, Armitage JM, Parish S. A comprehensive analysis of APOE genotype effects on human brain structure in the UK Biobank. Transl Psychiatry 2024; 14:143. [PMID: 38472178 PMCID: PMC10933274 DOI: 10.1038/s41398-024-02848-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Revised: 02/14/2024] [Accepted: 02/22/2024] [Indexed: 03/14/2024] Open
Abstract
Alzheimer's disease (AD) risk is increased in carriers of the apolipoprotein E (APOE) ε4 allele and decreased in ε2 allele carriers compared with the ε3ε3 genotype. The aim of this study was to determine whether: the APOE genotype affects brain grey (GM) or white matter (WM) structure; and if differences exist, the age when they become apparent and whether there are differential effects by sex. We used cross-sectional magnetic resonance imaging data from ~43,000 (28,494 after pre-processing) white British cognitively healthy participants (7,446 APOE ε4 carriers) aged 45-80 years from the UK Biobank cohort and investigated image-derived phenotypes (IDPs). We observed no statistically significant effects of APOE genotype on GM structure volumes or median T2* in subcortical structures, a measure related to iron content. The volume of white matter hyperintensities differed significantly between APOE genotype groups with higher volumes in APOE ε4ε4 (effect size 0.14 standard deviations [SD]) and ε3ε4 carriers (effect size 0.04 SD) but no differences in ε2 carriers compared with ε3ε3 carriers. WM integrity measures in the dorsal (mean diffusivity [MD]) and ventral cingulum (MD and intracellular volume fraction), posterior thalamic radiation (MD and isotropic volume fraction) and sagittal stratum (MD) indicated lower integrity in APOE ε4ε4 carriers (effect sizes around 0.2-0.3 SD) and ε3ε4 (effect sizes around 0.05 SD) carriers but no differences in ε2 carriers compared with the APOE ε3ε3 genotype. Effects did not differ between men and women. APOE ε4 homozygotes had lower WM integrity specifically at older ages with a steeper decline of WM integrity from the age of 60 that corresponds to around 5 years greater "brain age". APOE genotype affects various white matters measures, which might be indicative of preclinical AD processes. This hypothesis can be assessed in future when clinical outcomes become available.
Collapse
Affiliation(s)
- Verena Heise
- Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | - Alison Offer
- Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | - William Whiteley
- Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Clare E Mackay
- Department of Psychiatry, University of Oxford, Oxford, UK
- Wellcome Centre for Integrative Neuroimaging, Oxford Centre for Human Brain Activity, University of Oxford, Oxford, UK
| | - Jane M Armitage
- Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
- Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | - Sarah Parish
- Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
- Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
| |
Collapse
|
2
|
Van der Auwera S, Garvert L, Ameling S, Völzke H, Nauck M, Völker U, Grabe HJ. The interplay between micro RNAs and genetic liability to Alzheimer's Disease on memory trajectories in the general population. Psychiatry Res 2023; 323:115141. [PMID: 36905902 DOI: 10.1016/j.psychres.2023.115141] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/22/2022] [Revised: 02/20/2023] [Accepted: 02/28/2023] [Indexed: 03/13/2023]
Abstract
Deficits in cognitive function and memory are common early symptoms of neurodegenerative disorders, such as Alzheimer's Disease (AD). Several studies have discussed micro RNAs (miRNAs) as potential epigenetic early detection biomarkers. In a longitudinal general population sample (n = 548) from the Study of Health in Pomerania, we analyzed the associations between 167 baseline miRNA levels and changes in verbal memory scores with a mean follow-up time of 7.4 years. We additionally assessed the impact of an individual's genetic liability for AD on verbal memory scores in n = 2,334 subjects and a possible interactions between epigenetic and genetic markers. Results revealed two miRNAs associated with changes in immediate verbal memory over time. In interaction analyses between miRNAs and a polygenic risk score for AD, five miRNAs showed a significant interaction effect on changes in verbal memory. All of these miRNAs have previously been identified in the context of AD, neurodegeneration or cognition. Our study provides candidate miRNAs for a decline in verbal memory as an early symptom of neurodegeneration and AD. Further experimental studies are needed to verify the diagnostic value of these miRNA markers in the prodromal stage of AD.
Collapse
Affiliation(s)
- Sandra Van der Auwera
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany; German Center for Neurodegenerative Diseases DZNE, Site Rostock/Greifswald, Greifswald, Germany.
| | - Linda Garvert
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany
| | - Sabine Ameling
- Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany; German Centre for Cardiovascular Research (DZHK), Partner Site Greifswald, Greifswald, Germany
| | - Henry Völzke
- German Centre for Cardiovascular Research (DZHK), Partner Site Greifswald, Greifswald, Germany; Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany
| | - Matthias Nauck
- German Centre for Cardiovascular Research (DZHK), Partner Site Greifswald, Greifswald, Germany; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany
| | - Uwe Völker
- Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany; German Centre for Cardiovascular Research (DZHK), Partner Site Greifswald, Greifswald, Germany
| | - Hans J Grabe
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany; German Center for Neurodegenerative Diseases DZNE, Site Rostock/Greifswald, Greifswald, Germany
| |
Collapse
|
3
|
Deciphering the Effect of Different Genetic Variants on Hippocampal Subfield Volumes in the General Population. Int J Mol Sci 2023; 24:ijms24021120. [PMID: 36674637 PMCID: PMC9861136 DOI: 10.3390/ijms24021120] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Revised: 01/02/2023] [Accepted: 01/03/2023] [Indexed: 01/11/2023] Open
Abstract
The aim of this study was to disentangle the effects of various genetic factors on hippocampal subfield volumes using three different approaches: a biologically driven candidate gene approach, a hypothesis-free GWAS approach, and a polygenic approach, where AD risk alleles are combined with a polygenic risk score (PRS). The impact of these genetic factors was investigated in a large dementia-free general population cohort from the Study of Health in Pomerania (SHIP, n = 1806). Analyses were performed using linear regression models adjusted for biological and environmental risk factors. Hippocampus subfield volume alterations were found for APOE ε4, BDNF Val, and 5-HTTLPR L allele carriers. In addition, we were able to replicate GWAS findings, especially for rs17178139 (MSRB3), rs1861979 (DPP4), rs7873551 (ASTN2), and rs572246240 (MAST4). Interaction analyses between the significant SNPs as well as the PRS for AD revealed no significant results. Our results confirm that hippocampal volume reductions are influenced by genetic variation, and that different variants reveal different association patterns that can be linked to biological processes in neurodegeneration. Thus, this study underlines the importance of specific genetic analyses in the quest for acquiring deeper insights into the biology of hippocampal volume loss, memory impairment, depression, and neurodegenerative diseases.
Collapse
|
4
|
Kühn AL, Frenzel S, Teumer A, Wittfeld K, Garvert L, Weihs A, Homuth G, Prokisch H, Bülow R, Nauck M, Völker U, Völzke H, Grabe HJ, Van der Auwera S. TREML2 Gene Expression and Its Missense Variant rs3747742 Associate with White Matter Hyperintensity Volume and Alzheimer's Disease-Related Brain Atrophy in the General Population. Int J Mol Sci 2022; 23:ijms232213764. [PMID: 36430248 PMCID: PMC9692564 DOI: 10.3390/ijms232213764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2022] [Revised: 11/02/2022] [Accepted: 11/04/2022] [Indexed: 11/12/2022] Open
Abstract
Although the common pathology of Alzheimer's disease (AD) and white matter hyperintensities (WMH) is disputed, the gene TREML2 has been implicated in both conditions: its whole-blood gene expression was associated with WMH volume and its missense variant rs3747742 with AD risk. We re-examined those associations within one comprehensive dataset of the general population, additionally searched for cross-relations and illuminated the role of the apolipoprotein E (APOE) ε4 status in the associations. For our linear regression and linear mixed effect models, we used 1949 participants from the Study of Health in Pomerania (Germany). AD was assessed using a continuous pre-symptomatic MRI-based score evaluating a participant's AD-related brain atrophy. In our study, increased whole-blood TREML2 gene expression was significantly associated with reduced WMH volume but not with the AD score. Conversely, rs3747742-C was significantly associated with a reduced AD score but not with WMH volume. The APOE status did not influence the associations. In sum, TREML2 robustly associated with WMH volume and AD-related brain atrophy on different molecular levels. Our results thus underpin TREML2's role in neurodegeneration, might point to its involvement in AD and WMH via different biological mechanisms, and highlight TREML2 as a worthwhile target for disentangling the two pathologies.
Collapse
Affiliation(s)
- Annemarie Luise Kühn
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, 17475 Greifswald, Germany
- Correspondence: (A.L.K.); (S.V.d.A.)
| | - Stefan Frenzel
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, 17475 Greifswald, Germany
| | - Alexander Teumer
- Institute for Community Medicine, University Medicine Greifswald, 17475 Greifswald, Germany
| | - Katharina Wittfeld
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, 17475 Greifswald, Germany
- German Center for Neurodegenerative Diseases (DZNE), Site Rostock/Greifswald, 17489 Greifswald, Germany
| | - Linda Garvert
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, 17475 Greifswald, Germany
| | - Antoine Weihs
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, 17475 Greifswald, Germany
| | - Georg Homuth
- Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, 17475 Greifswald, Germany
| | - Holger Prokisch
- Institute of Human Genetics, Technical University Munich, 81675 Munich, Germany
- Institute of Neurogenomics, Helmholtz Zentrum München-German Research Center for Environmental Health, 85764 Neuherberg, Germany
| | - Robin Bülow
- Institute of Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, 17475 Greifswald, Germany
| | - Matthias Nauck
- Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, 17475 Greifswald, Germany
- German Centre for Cardiovascular Research (DZHK), Partner Site Greifswald, 17475 Greifswald, Germany
| | - Uwe Völker
- Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, 17475 Greifswald, Germany
- German Centre for Cardiovascular Research (DZHK), Partner Site Greifswald, 17475 Greifswald, Germany
| | - Henry Völzke
- Institute for Community Medicine, University Medicine Greifswald, 17475 Greifswald, Germany
- German Centre for Cardiovascular Research (DZHK), Partner Site Greifswald, 17475 Greifswald, Germany
| | - Hans Jörgen Grabe
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, 17475 Greifswald, Germany
- German Center for Neurodegenerative Diseases (DZNE), Site Rostock/Greifswald, 17489 Greifswald, Germany
| | - Sandra Van der Auwera
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, 17475 Greifswald, Germany
- German Center for Neurodegenerative Diseases (DZNE), Site Rostock/Greifswald, 17489 Greifswald, Germany
- Correspondence: (A.L.K.); (S.V.d.A.)
| |
Collapse
|
5
|
Li L, Yu X, Sheng C, Jiang X, Zhang Q, Han Y, Jiang J. A review of brain imaging biomarker genomics in Alzheimer’s disease: implementation and perspectives. Transl Neurodegener 2022; 11:42. [PMID: 36109823 PMCID: PMC9476275 DOI: 10.1186/s40035-022-00315-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2022] [Accepted: 08/24/2022] [Indexed: 11/25/2022] Open
Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disease with phenotypic changes closely associated with both genetic variants and imaging pathology. Brain imaging biomarker genomics has been developed in recent years to reveal potential AD pathological mechanisms and provide early diagnoses. This technique integrates multimodal imaging phenotypes with genetic data in a noninvasive and high-throughput manner. In this review, we summarize the basic analytical framework of brain imaging biomarker genomics and elucidate two main implementation scenarios of this technique in AD studies: (1) exploring novel biomarkers and seeking mutual interpretability and (2) providing a diagnosis and prognosis for AD with combined use of machine learning methods and brain imaging biomarker genomics. Importantly, we highlight the necessity of brain imaging biomarker genomics, discuss the strengths and limitations of current methods, and propose directions for development of this research field.
Collapse
|
6
|
Bonk S, Kirchner K, Ameling S, Garvert L, Völzke H, Nauck M, Völker U, Grabe HJ, Van der Auwera S. APOE ε4 in Depression-Associated Memory Impairment—Evidence from Genetic and MicroRNA Analyses. Biomedicines 2022; 10:biomedicines10071560. [PMID: 35884866 PMCID: PMC9313258 DOI: 10.3390/biomedicines10071560] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2022] [Revised: 06/27/2022] [Accepted: 06/29/2022] [Indexed: 11/16/2022] Open
Abstract
(1) Background: The aim of this study was to replicate a reported interaction between APOE ε4 status and depression on memory function in two independent, nondemented samples from the general population and to examine the potential role of circulating plasma miRNAs. (2) Methods: The impact of the APOE ε4 allele on verbal memory and the interaction with depression is investigated in two large general-population cohorts from the Study of Health in Pomerania (SHIP, total n = 6286). Additionally, biological insights are gained by examining the potential role of circulating plasma miRNAs as potential epigenetic regulators. Analyses are performed using linear regression models adjusted for relevant biological and environmental covariates. (3) Results: Current depression as well as carrying the APOE ε4 allele were associated with impaired memory performance, with increasing effect for subjects with both risk factors. In a subcohort with available miRNA data subjects with current depressive symptoms and carrying APOE e4 revealed reduced levels of hsa-miR-107, a prominent risk marker for early Alzheimer’s Disease. (4) Conclusions: Our results confirm the effect of depressive symptoms and APOE ε4 status on memory performance. Additionally, miRNA analysis identified hsa-miR-107 as a possible biological link between APOE ε4, depressive symptoms, and cognitive impairment.
Collapse
Affiliation(s)
- Sarah Bonk
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, 17489 Greifswald, Germany; (S.B.); (K.K.); (L.G.); (H.J.G.)
| | - Kevin Kirchner
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, 17489 Greifswald, Germany; (S.B.); (K.K.); (L.G.); (H.J.G.)
| | - Sabine Ameling
- Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, 17475 Greifswald, Germany; (S.A.); (U.V.)
- German Centre for Cardiovascular Research (DZHK), Partner Site Greifswald, 17475 Greifswald, Germany; (H.V.); (M.N.)
| | - Linda Garvert
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, 17489 Greifswald, Germany; (S.B.); (K.K.); (L.G.); (H.J.G.)
| | - Henry Völzke
- German Centre for Cardiovascular Research (DZHK), Partner Site Greifswald, 17475 Greifswald, Germany; (H.V.); (M.N.)
- Institute for Community Medicine, University Medicine Greifswald, 17475 Greifswald, Germany
| | - Matthias Nauck
- German Centre for Cardiovascular Research (DZHK), Partner Site Greifswald, 17475 Greifswald, Germany; (H.V.); (M.N.)
- Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, 17475 Greifswald, Germany
| | - Uwe Völker
- Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, 17475 Greifswald, Germany; (S.A.); (U.V.)
- German Centre for Cardiovascular Research (DZHK), Partner Site Greifswald, 17475 Greifswald, Germany; (H.V.); (M.N.)
| | - Hans J. Grabe
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, 17489 Greifswald, Germany; (S.B.); (K.K.); (L.G.); (H.J.G.)
- German Centre for Neurodegenerative Diseases (DZNE), Site Rostock/Greifswald, 17489 Greifswald, Germany
| | - Sandra Van der Auwera
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, 17489 Greifswald, Germany; (S.B.); (K.K.); (L.G.); (H.J.G.)
- German Centre for Neurodegenerative Diseases (DZNE), Site Rostock/Greifswald, 17489 Greifswald, Germany
- Correspondence:
| |
Collapse
|
7
|
Pitchika A, Markus MRP, Schipf S, Teumer A, Van der Auwera S, Nauck M, Dörr M, Felix S, Grabe HJ, Völzke H, Ittermann T. Effects of Apolipoprotein E polymorphism on carotid intima-media thickness, incident myocardial infarction and incident stroke. Sci Rep 2022; 12:5142. [PMID: 35332187 PMCID: PMC8948289 DOI: 10.1038/s41598-022-09129-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Accepted: 03/09/2022] [Indexed: 11/09/2022] Open
Abstract
The Apolipoprotein E (APOE) gene polymorphism (rs429358 and rs7412) shows a well-established association with lipid profiles, but its effect on cardiovascular disease is still conflicting. Therefore, we examined the association of different APOE alleles with common carotid artery intima-media thickness (CCA-IMT), carotid plaques, incident myocardial infarction (MI) and stroke. We analyzed data from 3327 participants aged 20-79 years of the population-based Study of Health in Pomerania (SHIP) from Northeast Germany with a median follow-up time of 14.5 years. Linear, logistic, and Cox-regression models were used to assess the associations of the APOE polymorphism with CCA-IMT, carotid plaques, incident MI and stroke, respectively. In our study, the APOE E2 allele was associated with lower CCA-IMT at baseline compared to E3 homozygotes (β: - 0.02 [95% CI - 0.04, - 0.004]). Over the follow-up, 244 MI events and 218 stroke events were observed. APOE E2 and E4 allele were not associated with incident MI (E2 HR: 1.06 [95% CI 0.68, 1.66]; E4 HR: 1.03 [95% CI 0.73, 1.45]) and incident stroke (E2 HR: 0.79 [95% CI 0.48, 1.30]; E4 HR: 0.96 [95% CI 0.66, 1.38]) in any of the models adjusting for potential confounders. However, the positive association between CCA-IMT and incident MI was more pronounced in E2 carriers than E3 homozygotes. Thus, our study suggests that while APOE E2 allele may predispose individuals to lower CCA-IMT, E2 carriers may be more prone to MI than E3 homozygotes as the CCA-IMT increases. APOE E4 allele had no effect on CCA-IMT, plaques, MI or stroke.
Collapse
Affiliation(s)
- Anitha Pitchika
- Institute for Community Medicine, University Medicine Greifswald, SHIP/Clinical-Epidemiological Research, Walther Rathenau Str. 48, 17475, Greifswald, Germany.
| | - Marcello Ricardo Paulista Markus
- Department of Internal Medicine B, University Medicine Greifswald, Greifswald, Germany.,German Center for Cardiovascular Research (DZHK E.V.), Partner site Greifswald, Greifswald, Germany.,DZD (German Center for Diabetes Research), Site Greifswald, Greifswald, Germany
| | - Sabine Schipf
- Institute for Community Medicine, University Medicine Greifswald, SHIP/Clinical-Epidemiological Research, Walther Rathenau Str. 48, 17475, Greifswald, Germany.,Department of Medicine A, University Medicine Greifswald, Greifswald, Germany
| | - Alexander Teumer
- Institute for Community Medicine, University Medicine Greifswald, SHIP/Clinical-Epidemiological Research, Walther Rathenau Str. 48, 17475, Greifswald, Germany.,German Center for Cardiovascular Research (DZHK E.V.), Partner site Greifswald, Greifswald, Germany
| | - Sandra Van der Auwera
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany.,German Center for Neurodegenerative Diseases (DZNE), Site Rostock/Greifswald, Greifswald, Germany
| | - Matthias Nauck
- German Center for Cardiovascular Research (DZHK E.V.), Partner site Greifswald, Greifswald, Germany.,Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany
| | - Marcus Dörr
- Department of Internal Medicine B, University Medicine Greifswald, Greifswald, Germany.,German Center for Cardiovascular Research (DZHK E.V.), Partner site Greifswald, Greifswald, Germany
| | - Stephan Felix
- Department of Internal Medicine B, University Medicine Greifswald, Greifswald, Germany.,German Center for Cardiovascular Research (DZHK E.V.), Partner site Greifswald, Greifswald, Germany
| | - Hans-Jörgen Grabe
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany.,German Center for Neurodegenerative Diseases (DZNE), Site Rostock/Greifswald, Greifswald, Germany
| | - Henry Völzke
- Institute for Community Medicine, University Medicine Greifswald, SHIP/Clinical-Epidemiological Research, Walther Rathenau Str. 48, 17475, Greifswald, Germany.,German Center for Cardiovascular Research (DZHK E.V.), Partner site Greifswald, Greifswald, Germany.,DZD (German Center for Diabetes Research), Site Greifswald, Greifswald, Germany
| | - Till Ittermann
- Institute for Community Medicine, University Medicine Greifswald, SHIP/Clinical-Epidemiological Research, Walther Rathenau Str. 48, 17475, Greifswald, Germany
| |
Collapse
|
8
|
Pitchika A, Markus MRP, Schipf S, Teumer A, Van der Auwera S, Nauck M, Dörr M, Felix S, Jörgen Grabe H, Völzke H, Ittermann T. Longitudinal association of Apolipoprotein E polymorphism with lipid profile, type 2 diabetes and metabolic syndrome: Results from a 15 year follow-up study. Diabetes Res Clin Pract 2022; 185:109778. [PMID: 35167921 DOI: 10.1016/j.diabres.2022.109778] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Revised: 01/24/2022] [Accepted: 02/08/2022] [Indexed: 01/22/2023]
Abstract
AIMS To examine the association of different APOE alleles with type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) as well as the influence of high-sensitive C-reactive protein (hs-CRP) on these associations. METHODS We analyzed data from 3917 participants aged 20-81 years of the population-based Study of Health in Pomerania (SHIP) from Northeast Germany with a median follow-up time of 10.8 years. Linear and logistic mixed models were performed to test the association of APOE alleles with T2DM and MetS. RESULTS We observed 393 T2DM and 1411 MetS events at baseline, and 576 T2DM and 1342 MetS events over the follow-up. The E4 carriers had a lower odds of developing T2DM (OR: 0.47 [0.24, 0.94]) than E3 homozygotes even after adjustment for potential confounders. The E2 carriers showed no associations. The inverse association between E4 alleles and T2DM moderately attenuated after adjustment for hs-CRP levels. The lower odds of developing T2DM in E4 carriers was more pronounced in participants without obesity, hypertension or MetS. However, both E2 and E4 carriers had higher odds of developing MetS (E2 OR: 1.45 [1.03, 2.03]; E4 OR: 1.56 [1.17, 2.09]) than E3 homozygotes. CONCLUSIONS While the presence of APOE E4 allele might increase the chance of MetS through its major action on lipids, E4 allele might offer a protection towards T2DM through its influence on inflammation.
Collapse
Affiliation(s)
- Anitha Pitchika
- Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany.
| | - Marcello Ricardo Paulista Markus
- Department of Internal Medicine B, University Medicine Greifswald, Greifswald, Germany; German Center for Cardiovascular Research (DZHK e.V.), Partner site Greifswald, Greifswald, Germany; DZD (German Center for Diabetes Research), Site Greifswald, Greifswald, Germany
| | - Sabine Schipf
- Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany; Department of Medicine A, University Medicine Greifswald, Greifswald, Germany
| | - Alexander Teumer
- Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany; German Center for Cardiovascular Research (DZHK e.V.), Partner site Greifswald, Greifswald, Germany
| | - Sandra Van der Auwera
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany; German Center for Neurodegenerative Diseases (DZNE), Site Rostock, Greifswald, Germany
| | - Matthias Nauck
- German Center for Cardiovascular Research (DZHK e.V.), Partner site Greifswald, Greifswald, Germany; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany
| | - Marcus Dörr
- Department of Internal Medicine B, University Medicine Greifswald, Greifswald, Germany; German Center for Cardiovascular Research (DZHK e.V.), Partner site Greifswald, Greifswald, Germany
| | - Stephan Felix
- Department of Internal Medicine B, University Medicine Greifswald, Greifswald, Germany; German Center for Cardiovascular Research (DZHK e.V.), Partner site Greifswald, Greifswald, Germany
| | - Hans Jörgen Grabe
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany; German Center for Neurodegenerative Diseases (DZNE), Site Rostock, Greifswald, Germany
| | - Henry Völzke
- Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany; German Center for Cardiovascular Research (DZHK e.V.), Partner site Greifswald, Greifswald, Germany; DZD (German Center for Diabetes Research), Site Greifswald, Greifswald, Germany
| | - Till Ittermann
- Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany
| |
Collapse
|
9
|
Zheng Y, Habes M, Gonzales M, Pomponio R, Nasrallah I, Khan S, Vaughan DE, Davatzikos C, Seshadri S, Launer L, Sorond F, Sedaghat S, Wainwright D, Baccarelli A, Sidney S, Bryan N, Greenland P, Lloyd-Jones D, Yaffe K, Hou L. Mid-life epigenetic age, neuroimaging brain age, and cognitive function: coronary artery risk development in young adults (CARDIA) study. Aging (Albany NY) 2022; 14:1691-1712. [PMID: 35220276 PMCID: PMC8908939 DOI: 10.18632/aging.203918] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2021] [Accepted: 02/08/2022] [Indexed: 11/25/2022]
Abstract
The proportion of aging populations affected by dementia is increasing. There is an urgent need to identify biological aging markers in mid-life before symptoms of age-related dementia present for early intervention to delay the cognitive decline and the onset of dementia. In this cohort study involving 1,676 healthy participants (mean age 40) with up to 15 years of follow up, we evaluated the associations between cognitive function and two classes of novel biological aging markers: blood-based epigenetic aging and neuroimaging-based brain aging. Both accelerated epigenetic aging and brain aging were prospectively associated with worse cognitive outcomes. Specifically, every year faster epigenetic or brain aging was on average associated with 0.19-0.28 higher (worse) Stroop score, 0.04-0.05 lower (worse) RAVLT score, and 0.23-0.45 lower (worse) DSST (all false-discovery-rate-adjusted p <0.05). While epigenetic aging is a more stable biomarker with strong long-term predictive performance for cognitive function, brain aging biomarker may change more dynamically in temporal association with cognitive decline. The combined model using epigenetic and brain aging markers achieved the highest accuracy (AUC: 0.68, p<0.001) in predicting global cognitive function status. Accelerated epigenetic age and brain age at midlife may aid timely identification of individuals at risk for accelerated cognitive decline and promote the development of interventions to preserve optimal functioning across the lifespan.
Collapse
Affiliation(s)
- Yinan Zheng
- Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Mohamad Habes
- Biggs Institute Neuroimaging Core, Glenn Biggs Institute for Neurodegenerative Disorders, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
- Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Mitzi Gonzales
- Biggs Institute Neuroimaging Core, Glenn Biggs Institute for Neurodegenerative Disorders, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
| | - Raymond Pomponio
- Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Ilya Nasrallah
- Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Sadiya Khan
- Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
- Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Douglas E. Vaughan
- Feinberg Cardiovascular Research Institute, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Christos Davatzikos
- Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Sudha Seshadri
- Biggs Institute Neuroimaging Core, Glenn Biggs Institute for Neurodegenerative Disorders, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
- Department of Neurology, Boston University School of Medicine, Boston, MA 02118, USA
| | - Lenore Launer
- Laboratory of Epidemiology and Population Science, Intramural Research Program, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA
| | - Farzaneh Sorond
- Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Sanaz Sedaghat
- Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN 55455, USA
| | - Derek Wainwright
- Departments of Neurological Surgery, Medicine-Hematology and Oncology, Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Andrea Baccarelli
- Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, NY 10032, USA
| | - Stephen Sidney
- Kaiser Permanente Division of Research, Oakland, CA 94612, USA
| | - Nick Bryan
- Department of Diagnostic Medicine, Dell Medical School, University of Texas at Austin, Austin, TX 78712, USA
| | - Philip Greenland
- Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Donald Lloyd-Jones
- Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Kristine Yaffe
- Departments of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA 94143, USA
- Department of Neurology University of California, San Francisco, CA 94143, USA
- Department of Epidemiology and Biostatistics, University of California San Francisco, CA 94143, USA
- San Francisco VA Medical Center, San Francisco, CA 94143, USA
| | - Lifang Hou
- Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| |
Collapse
|
10
|
Jacobs HIL, O'Donnell A, Satizabal CL, Lois C, Kojis D, Hanseeuw BJ, Thibault E, Sanchez JS, Buckley RF, Yang Q, DeCarli C, Killiany R, Sargurupremraj M, Sperling RA, Johnson KA, Beiser AS, Seshadri S. Associations Between Brainstem Volume and Alzheimer's Disease Pathology in Middle-Aged Individuals of the Framingham Heart Study. J Alzheimers Dis 2022; 86:1603-1609. [PMID: 35213372 PMCID: PMC9038711 DOI: 10.3233/jad-215372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The brainstem is among the first regions to accumulate Alzheimer's disease (AD)-related hyperphosphorylated tau pathology during aging. We aimed to examine associations between brainstem volume and neocortical amyloid-β or tau pathology in 271 middle-aged clinically normal individuals of the Framingham Heart Study who underwent MRI and PET imaging. Lower volume of the medulla, pons, or midbrain was associated with greater neocortical amyloid burden. No associations were detected between brainstem volumes and tau deposition. Our results support the hypothesis that lower brainstem volumes are associated with initial AD-related processes and may signal preclinical AD pathology.
Collapse
Affiliation(s)
- Heidi I L Jacobs
- Massachusetts General Hospital, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
- School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht University, Maastricht, Netherlands
- Gordon Center for Medical Imaging, Boston, MA, USA
| | - Adrienne O'Donnell
- Boston University School of Public Health, Boston, MA, USA
- The Framingham Heart Study, Framingham, MA, USA
| | - Claudia L Satizabal
- The Framingham Heart Study, Framingham, MA, USA
- Boston University School of Medicine, Boston, MA, USA
- Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX, USA
| | - Cristina Lois
- Massachusetts General Hospital, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
- Gordon Center for Medical Imaging, Boston, MA, USA
| | - Daniel Kojis
- Boston University School of Public Health, Boston, MA, USA
- The Framingham Heart Study, Framingham, MA, USA
| | - Bernard J Hanseeuw
- Massachusetts General Hospital, Boston, MA, USA
- Gordon Center for Medical Imaging, Boston, MA, USA
- Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Emma Thibault
- Massachusetts General Hospital, Boston, MA, USA
- Gordon Center for Medical Imaging, Boston, MA, USA
| | - Justin S Sanchez
- Massachusetts General Hospital, Boston, MA, USA
- Gordon Center for Medical Imaging, Boston, MA, USA
| | - Rachel F Buckley
- Massachusetts General Hospital, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
- Melbourne School of Psychological Sciences, University of Melbourne, Victoria, Australia
| | - Qiong Yang
- Boston University School of Public Health, Boston, MA, USA
| | | | - Ron Killiany
- Boston University School of Medicine, Boston, MA, USA
| | - Muralidharan Sargurupremraj
- Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX, USA
| | - Reisa A Sperling
- Massachusetts General Hospital, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
- Brigham and Women's Hospital, Boston, MA, USA
| | - Keith A Johnson
- Massachusetts General Hospital, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
- Gordon Center for Medical Imaging, Boston, MA, USA
- Brigham and Women's Hospital, Boston, MA, USA
| | - Alexa S Beiser
- Boston University School of Public Health, Boston, MA, USA
- The Framingham Heart Study, Framingham, MA, USA
- Boston University School of Medicine, Boston, MA, USA
| | - Sudha Seshadri
- The Framingham Heart Study, Framingham, MA, USA
- Boston University School of Medicine, Boston, MA, USA
- Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX, USA
| |
Collapse
|
11
|
Zuroff L, Wisse LEM, Glenn T, Xie SX, Nasrallah IM, Habes M, Dubroff J, de Flores R, Xie L, Yushkevich P, Doshi J, Davatsikos C, Shaw LM, Tropea TF, Chen-Plotkin AS, Wolk DA, Das S, Mechanic-Hamilton D. Self- and Partner-Reported Subjective Memory Complaints: Association with Objective Cognitive Impairment and Risk of Decline. J Alzheimers Dis Rep 2022; 6:411-430. [PMID: 36072364 PMCID: PMC9397901 DOI: 10.3233/adr-220013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/24/2022] [Indexed: 11/15/2022] Open
Abstract
Background Episodic memory decline is a hallmark of Alzheimer's disease (AD). Subjective memory complaints (SMCs) may represent one of the earliest signs of impending cognitive decline. The degree to which self- or partner-reported SMCs predict cognitive change remains unclear. Objective We aimed to evaluate the relationship between self- and partner-reported SMCs, objective cognitive performance, AD biomarkers, and risk of future decline in a well-characterized longitudinal memory center cohort. We also evaluated whether study partner characteristics influence reports of SMCs. Methods 758 participants and 690 study partners were recruited from the Penn Alzheimer's Disease Research Center Clinical Core. Participants included those with Normal Cognition, Mild Cognitive Impairment, and AD. SMCs were measured using the Prospective and Retrospective Memory Questionnaire (PRMQ), and were evaluated for their association with cognition, genetic, plasma, and neuroimaging biomarkers of AD, cognitive and functional decline, and diagnostic progression over an average of four years. Results We found that partner-reported SMCs were more consistent with cognitive test performance and increasing symptom severity than self-reported SMCs. Partner-reported SMCs showed stronger correlations with AD-associated brain atrophy, plasma biomarkers of neurodegeneration, and longitudinal cognitive and functional decline. A 10-point increase on baseline PRMQ increased the annual risk of diagnostic progression by approximately 70%. Study partner demographics and relationship to participants influenced reports of SMCs in AD participants only. Conclusion Partner-reported SMCs, using the PRMQ, have a stronger relationship with the neuroanatomic and cognitive changes associated with AD than patient-reported SMCs. Further work is needed to evaluate whether SMCs could be used to screen for future decline.
Collapse
Affiliation(s)
- Leah Zuroff
- Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Laura EM Wisse
- Department of Diagnostic Radiology, Lund University, Lund, Sweden
| | - Trevor Glenn
- Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Sharon X. Xie
- Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, USA
| | - Ilya M. Nasrallah
- Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia, PA, USA
| | - Mohamad Habes
- Neuroimage Analytics Laboratory (NAL) and the Biggs Institute Neuroimaging Core (BINC), Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases, University of Texas Health Science Center San Antonio (UTHSCSA), San Antonio, TX, USA
| | - Jacob Dubroff
- Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
| | - Robin de Flores
- Université de Caen Normandie, INSERM UMRS U1237, Caen, France
| | - Long Xie
- Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
| | - Paul Yushkevich
- Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
| | - Jimit Doshi
- Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia, PA, USA
| | - Christos Davatsikos
- Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia, PA, USA
| | - Leslie M. Shaw
- Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
| | - Thomas F. Tropea
- Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Alice S. Chen-Plotkin
- Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - David A Wolk
- Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Sandhitsu Das
- Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Dawn Mechanic-Hamilton
- Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- Correspondence to: Dawn Mechanic-Hamilton, PCAM-2 South, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA. Tel.: +1 215 662 4516; E-mail:
| |
Collapse
|
12
|
Piersson AD, Mohamad M, Suppiah S, Rajab NF. Topographical patterns of whole-brain structural alterations in association with genetic risk, cerebrospinal fluid, positron emission tomography biomarkers of Alzheimer’s disease, and neuropsychological measures. Clin Transl Imaging 2021. [DOI: 10.1007/s40336-021-00440-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
13
|
Hippocampal subfield volumes across the healthy lifespan and the effects of MR sequence on estimates. Neuroimage 2021; 233:117931. [DOI: 10.1016/j.neuroimage.2021.117931] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2021] [Accepted: 02/28/2021] [Indexed: 01/18/2023] Open
|
14
|
Goltermann J, Repple J, Redlich R, Dohm K, Flint C, Grotegerd D, Waltemate L, Lemke H, Fingas SM, Meinert S, Enneking V, Hahn T, Bauer J, Schmitt S, Meller T, Stein F, Brosch K, Steinsträter O, Jansen A, Krug A, Nenadić I, Baune BT, Rietschel M, Witt S, Forstner AJ, Nöthen M, Johnen A, Alferink J, Kircher T, Dannlowski U, Opel N. Apolipoprotein E homozygous ε4 allele status: Effects on cortical structure and white matter integrity in a young to mid-age sample. Eur Neuropsychopharmacol 2021; 46:93-104. [PMID: 33648793 DOI: 10.1016/j.euroneuro.2021.02.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/29/2020] [Revised: 01/04/2021] [Accepted: 02/09/2021] [Indexed: 11/16/2022]
Abstract
Apolipoprotein E (APOE) genotype is the strongest single gene predictor of Alzheimer's disease (AD) and has been frequently associated with AD-related brain structural alterations before the onset of dementia. While previous research has primarily focused on hippocampal morphometry in relation to APOE, sporadic recent findings have questioned the specificity of the hippocampus and instead suggested more global effects on the brain. With the present study we aimed to investigate associations between homozygous APOE ε4 status and cortical gray matter structure as well as white matter microstructure. In our study, we contrasted n = 31 homozygous APOE ε4 carriers (age=34.47 years, including a subsample of n = 12 subjects with depression) with a demographically matched sample without an ε4 allele (resulting total sample: N = 62). Morphometry analyses included a) Freesurfer based cortical segmentations of thickness and surface area measures and b) tract based spatial statistics of DTI measures. We found pronounced and widespread reductions in cortical surface area of ε4 homozygotes in 57 out of 68 cortical brain regions. In contrast, no differences in cortical thickness were observed. Furthermore, APOE ε4 homozygous carriers showed significantly lower fractional anisotropy in the corpus callosum, the right internal and external capsule, the left corona radiata and the right fornix. The present findings support a global rather than regionally specific effect of homozygous APOE ε4 allele status on cortical surface area and white matter microstructure. Future studies should aim to delineate the clinical implications of these findings.
Collapse
Affiliation(s)
- Janik Goltermann
- Department of Psychiatry, University of Münster, Münster, Germany
| | - Jonathan Repple
- Department of Psychiatry, University of Münster, Münster, Germany
| | - Ronny Redlich
- Department of Psychiatry, University of Münster, Münster, Germany
| | - Katharina Dohm
- Department of Psychiatry, University of Münster, Münster, Germany
| | - Claas Flint
- Department of Psychiatry, University of Münster, Münster, Germany; Department of Mathematics and Computer Science, University of Münster, Germany
| | | | - Lena Waltemate
- Department of Psychiatry, University of Münster, Münster, Germany
| | - Hannah Lemke
- Department of Psychiatry, University of Münster, Münster, Germany
| | | | - Susanne Meinert
- Department of Psychiatry, University of Münster, Münster, Germany
| | - Verena Enneking
- Department of Psychiatry, University of Münster, Münster, Germany
| | - Tim Hahn
- Department of Psychiatry, University of Münster, Münster, Germany
| | - Jochen Bauer
- Institute of Clinical Radiology, University of Münster, Germany
| | - Simon Schmitt
- Department of Psychiatry, University of Marburg, Germany
| | - Tina Meller
- Department of Psychiatry, University of Marburg, Germany
| | | | | | | | - Andreas Jansen
- Department of Psychiatry, University of Marburg, Germany
| | - Axel Krug
- Department of Psychiatry, University of Marburg, Germany
| | - Igor Nenadić
- Department of Psychiatry, University of Marburg, Germany
| | - Bernhard T Baune
- Department of Psychiatry, University of Münster, Münster, Germany; Department of Psychiatry, Melbourne Medical School, The University of Melbourne, Melbourne, VIC, Australia
| | - Marcella Rietschel
- Department of Genetic Epidemiology, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany
| | - Stephanie Witt
- Department of Genetic Epidemiology, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany
| | - Andreas J Forstner
- Institute of Human Genetics, Department of Genomics, Life & Brain Center, University of Bonn, Germany; Department of Biomedicine, University of Basel, Basel, Switzerland
| | - Markus Nöthen
- Institute of Human Genetics, Department of Genomics, Life & Brain Center, University of Bonn, Germany
| | | | - Judith Alferink
- Department of Psychiatry, University of Münster, Münster, Germany; Cells in Motion Interfaculty Centre, Münster, Germany
| | - Tilo Kircher
- Department of Psychiatry, University of Marburg, Germany
| | - Udo Dannlowski
- Department of Psychiatry, University of Münster, Münster, Germany.
| | - Nils Opel
- Department of Psychiatry, University of Münster, Münster, Germany
| |
Collapse
|
15
|
Janowitz D, Habes M, Toledo JB, Hannemann A, Frenzel S, Terock J, Davatzikos C, Hoffmann W, Grabe HJ. Inflammatory markers and imaging patterns of advanced brain aging in the general population. Brain Imaging Behav 2021; 14:1108-1117. [PMID: 30820858 DOI: 10.1007/s11682-019-00058-y] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Inflammaging describes the complexity between low-grade chronic inflammation with the pathogenesis of brain aging and Alzheimer´s disease (AD). We aimed to find associations of inflammatory markers: i) white blood cell count (WBC), ii) high-sensitivity C-reactive protein (hs-CRP), and iii) fibrinogen with brain structures, sensitive neuroimaging markers of advanced brain aging and AD-like atrophy, and cognitive aging scores. We analyzed magnetic resonance imaging (MRI) scans of 2204 participants from the Study of Health in Pomerania-2 (SHIP-2) and SHIP-Trend (55.6% women, mean age 52.4±13.7 years). Associations of the inflammatory markers with specific brain signatures of brain aging (SPARE-BA), AD-like brain atrophy (SPARE-AD) and white matter disease (white matter hyperintensities volume (WMHV)) were investigated. Furthermore we explored their association with general brain structures including total brain volume (TBV), gray matter volume (GMV), and white matter volume (WMV), as well as cognitive scores (Nurnberger Age Inventory (NAI); Verbal Learning and Memory Test (VLMT). We adjusted for multiple vascular risk factors (VRF; e.g. smoking and blood pressure) and corresponding medication use to take their brain aging effects into account and corrected for false-discovery rate (FDR). Results:WBC was inversely associated with SPARE-BA (FDR-adjusted p=0.003), TBV (FDR-adjusted p=0.019) and GMV (FDR-adjusted p= 0.017). GMV was also inversely associated with hs-CRP (FDR-adjusted p=0.039) and fibrinogen (FDR-adjusted p=0.039). None of the inflammatory markers was associated with WMHV. Regression analysis also revealed a trend-level interaction between intake of antiinflammatory medication and hs-CRP with brain aging (SPARE-BA; FDR-adjusted p=0.062). Inflammatatory markers are associated with neuroimaging markers, with elevated WBC leading to significant acceleration in brain aging patterns but not with AD-like imaging structural changes. Given the overlap between accelerated brain aging and AD-like atrophy, increased WBC might be associated with global dementia symptoms due to this overlap in atrophy patterns. Elevated WBC may be not causal to preclinical AD dementia, but an accessory symptom of inflammaging. At population level, our results support the relevant roles of inflammatory markers on brain aging related atrophy.
Collapse
Affiliation(s)
- Deborah Janowitz
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475, Greifswald, Germany.
| | - Mohamad Habes
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475, Greifswald, Germany.
- Section of Biomedical Image Analysis, Department of Radiology, University of Pennsylvania, 3700 Hamiton Walk, Richards Building, Philadelphia, PA, 19104, USA.
- Institute for Community Medicine, University Medicine Greifswald, Ellernholzstr. 1-2, 17475, Greifswald, Germany.
| | - Jon B Toledo
- Department of Neurology, Stanley H. Appel Department of Neurology, Houston Methodist Hospital, 6560 Fannin St. Scurlock Tower, Houston, TX, 77030, USA
| | - Anke Hannemann
- Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, F.-Sauerbruchstr, 17475, Greifswald, Germany
| | - Stefan Frenzel
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475, Greifswald, Germany
| | - Jan Terock
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475, Greifswald, Germany
- Department of Psychiatry and Psychotherapy, HELIOS Hospital Stralsund, University Medicine Greifswald, Rostocker Chaussee 70, 18437, Stralsund, Germany
| | - Christos Davatzikos
- Section of Biomedical Image Analysis, Department of Radiology, University of Pennsylvania, 3700 Hamiton Walk, Richards Building, Philadelphia, PA, 19104, USA
| | - Wolfgang Hoffmann
- Institute for Community Medicine, University Medicine Greifswald, Ellernholzstr. 1-2, 17475, Greifswald, Germany
- German Center for Neurodegenerative Diseases (DZNE), Site Rostock/Greifswald, Ellernholzstr. 1-2, 17475, Greifswald, Germany
| | - Hans Jörgen Grabe
- Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475, Greifswald, Germany
- German Center for Neurodegenerative Diseases (DZNE), Site Rostock/Greifswald, Ellernholzstr. 1-2, 17475, Greifswald, Germany
| |
Collapse
|
16
|
Associated factors of white matter hyperintensity volume: a machine-learning approach. Sci Rep 2021; 11:2325. [PMID: 33504924 PMCID: PMC7840689 DOI: 10.1038/s41598-021-81883-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2020] [Accepted: 01/11/2021] [Indexed: 01/08/2023] Open
Abstract
To identify the most important parameters associated with cerebral white matter hyperintensities (WMH), in consideration of potential collinearity, we used a data-driven machine-learning approach. We analysed two independent cohorts (KORA and SHIP). WMH volumes were derived from cMRI-images (FLAIR). 90 (KORA) and 34 (SHIP) potential determinants of WMH including measures of diabetes, blood-pressure, medication-intake, sociodemographics, life-style factors, somatic/depressive-symptoms and sleep were collected. Elastic net regression was used to identify relevant predictor covariates associated with WMH volume. The ten most frequently selected variables in KORA were subsequently examined for robustness in SHIP. The final KORA sample consisted of 370 participants (58% male; age 55.7 ± 9.1 years), the SHIP sample comprised 854 participants (38% male; age 53.9 ± 9.3 years). The most often selected and highly replicable parameters associated with WMH volume were in descending order age, hypertension, components of the social environment (i.e. widowed, living alone) and prediabetes. A systematic machine-learning based analysis of two independent, population-based cohorts showed, that besides age and hypertension, prediabetes and components of the social environment might play important roles in the development of WMH. Our results enable personal risk assessment for the development of WMH and inform prevention strategies tailored to the individual patient.
Collapse
|
17
|
Henson RN, Suri S, Knights E, Rowe JB, Kievit RA, Lyall DM, Chan D, Eising E, Fisher SE. Effect of apolipoprotein E polymorphism on cognition and brain in the Cambridge Centre for Ageing and Neuroscience cohort. Brain Neurosci Adv 2020; 4:2398212820961704. [PMID: 33088920 PMCID: PMC7545750 DOI: 10.1177/2398212820961704] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2019] [Accepted: 08/27/2020] [Indexed: 01/01/2023] Open
Abstract
Polymorphisms in the apolipoprotein E (APOE) gene have been associated with individual differences in cognition, brain structure and brain function. For example, the ε4 allele has been associated with cognitive and brain impairment in old age and increased risk of dementia, while the ε2 allele has been claimed to be neuroprotective. According to the ‘antagonistic pleiotropy’ hypothesis, these polymorphisms have different effects across the lifespan, with ε4, for example, postulated to confer benefits on cognitive and brain functions earlier in life. In this stage 2 of the Registered Report – https://osf.io/bufc4, we report the results from the cognitive and brain measures in the Cambridge Centre for Ageing and Neuroscience cohort (www.cam-can.org). We investigated the antagonistic pleiotropy hypothesis by testing for allele-by-age interactions in approximately 600 people across the adult lifespan (18–88 years), on six outcome variables related to cognition, brain structure and brain function (namely, fluid intelligence, verbal memory, hippocampal grey-matter volume, mean diffusion within white matter and resting-state connectivity measured by both functional magnetic resonance imaging and magnetoencephalography). We found no evidence to support the antagonistic pleiotropy hypothesis. Indeed, Bayes factors supported the null hypothesis in all cases, except for the (linear) interaction between age and possession of the ε4 allele on fluid intelligence, for which the evidence for faster decline in older ages was ambiguous. Overall, these pre-registered analyses question the antagonistic pleiotropy of APOE polymorphisms, at least in healthy adults.
Collapse
Affiliation(s)
- Richard N Henson
- MRC Cognition & Brain Sciences Unit, University of Cambridge, Cambridge, UK.,Department of Psychiatry, University of Cambridge, Cambridge, UK
| | - Sana Suri
- Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK.,Wellcome Centre for Integrative Neuroimaging, University of Oxford, Oxford, UK
| | - Ethan Knights
- MRC Cognition & Brain Sciences Unit, University of Cambridge, Cambridge, UK
| | - James B Rowe
- MRC Cognition & Brain Sciences Unit, University of Cambridge, Cambridge, UK.,Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
| | - Rogier A Kievit
- MRC Cognition & Brain Sciences Unit, University of Cambridge, Cambridge, UK
| | - Donald M Lyall
- Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
| | - Dennis Chan
- Institute of Cognitive Neuroscience, University College London, London, UK
| | - Else Eising
- Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, The Netherlands
| | - Simon E Fisher
- Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, The Netherlands.,Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, The Netherlands
| |
Collapse
|
18
|
Toledo JB, Habes M, Sotiras A, Bjerke M, Fan Y, Weiner MW, Shaw LM, Davatzikos C, Trojanowski JQ. APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points. J Alzheimers Dis 2020; 69:783-793. [PMID: 31127775 DOI: 10.3233/jad-181282] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
There are conflicting results regarding how APOE genotype, the strongest genetic risk factor for Alzheimer's disease (AD), influences spatial and longitudinal amyloid-β (Aβ) deposition and its impact on the selection of biomarker cut-points. In our study, we sought to determine the impact of APOE genotype on cross-sectional and longitudinal florbetapir positron emission tomography (PET) amyloid measures and its impact in classification of patients and interpretation of clinical cohort results. We included 1,019 and 1,072 Alzheimer's Disease Neuroimaging Initiative participants with cerebrospinal fluid Aβ1 - 42 and florbetapir PET values, respectively. 623 of these subjects had a second florbetapir PET scans two years after the baseline visit. We evaluated the effect of APOE genotype on Aβ distribution pattern, pathological biomarker cut-points, cross-sectional clinical associations with Aβ load, and longitudinal Aβ deposition rate measured using florbetapir PET scans. 1) APOEɛ4 genotype influences brain amyloid deposition pattern; 2) APOEɛ4 genotype does not modify Aβ biomarker cut-points estimated using unsupervised mixture modeling methods if white matter and brainstem references are used (but not when cerebellum is used as a reference); 3) findings of large differences in Aβ biomarker value differences based on APOE genotype are due to increased probability of having AD neuropathology and are most significant in mild cognitive impairment subjects; and 4) APOE genotype and age (but not gender) were associated with increased Aβ deposition rate. APOEɛ4 carrier status affects rate and location of brain Aβ deposition but does not affect choice of biomarker cut-points if adequate references are selected for florbetapir PET processing.
Collapse
Affiliation(s)
- Jon B Toledo
- Department of Pathology & Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.,Department of Neurology, Houston Methodist Hospital, Houston, TX, USA
| | - Mohamad Habes
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia, PA, USA
| | - Aristeidis Sotiras
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia, PA, USA.,Department of Radiology, Washington University in St. Louis, St. Louis, MO, USA
| | - Maria Bjerke
- Department of Pathology & Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.,Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium
| | - Yong Fan
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia, PA, USA
| | - Michael W Weiner
- Department of Radiology, Center for Imaging of Neurodegenerative Diseases, San Francisco VA Medical Center/University of California San Francisco, San Francisco, CA, USA
| | - Leslie M Shaw
- Department of Pathology & Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
| | - Christos Davatzikos
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia, PA, USA
| | - John Q Trojanowski
- Department of Pathology & Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
| | | |
Collapse
|
19
|
Srinivasan D, Erus G, Doshi J, Wolk DA, Shou H, Habes M, Davatzikos C. A comparison of Freesurfer and multi-atlas MUSE for brain anatomy segmentation: Findings about size and age bias, and inter-scanner stability in multi-site aging studies. Neuroimage 2020; 223:117248. [PMID: 32860881 DOI: 10.1016/j.neuroimage.2020.117248] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2020] [Accepted: 08/04/2020] [Indexed: 12/28/2022] Open
Abstract
Automatic segmentation of brain anatomy has been a key processing step in quantitative neuroimaging analyses. An extensive body of literature has relied on Freesurfer segmentations. Yet, in recent years, the multi-atlas segmentation framework has consistently obtained results with superior accuracy in various evaluations. We compared brain anatomy segmentations from Freesurfer, which uses a single probabilistic atlas strategy, against segmentations from Multi-atlas region Segmentation utilizing Ensembles of registration algorithms and parameters and locally optimal atlas selection (MUSE), one of the leading ensemble-based methods that calculates a consensus segmentation through fusion of anatomical labels from multiple atlases and registrations. The focus of our evaluation was twofold. First, using manual ground-truth hippocampus segmentations, we found that Freesurfer segmentations showed a bias towards over-segmentation of larger hippocampi, and under-segmentation in older age. This bias was more pronounced in Freesurfer-v5.3, which has been used in multiple previous studies of aging, while the effect was mitigated in more recent Freesurfer-v6.0, albeit still present. Second, we evaluated inter-scanner segmentation stability using same day scan pairs from ADNI acquired on 1.5T and 3T scanners. We also found that MUSE obtains more consistent segmentations across scanners compared to Freesurfer, particularly in the deep structures.
Collapse
Affiliation(s)
- Dhivya Srinivasan
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Richards Building, 3700 Hamilton Walk, 7th Floor, Philadelphia, PA 19104, United States.
| | - Guray Erus
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Richards Building, 3700 Hamilton Walk, 7th Floor, Philadelphia, PA 19104, United States
| | - Jimit Doshi
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Richards Building, 3700 Hamilton Walk, 7th Floor, Philadelphia, PA 19104, United States
| | - David A Wolk
- Department of Neurology, University of Pennsylvania, United States
| | - Haochang Shou
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Richards Building, 3700 Hamilton Walk, 7th Floor, Philadelphia, PA 19104, United States; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, United States
| | - Mohamad Habes
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Richards Building, 3700 Hamilton Walk, 7th Floor, Philadelphia, PA 19104, United States; Department of Neurology, University of Pennsylvania, United States
| | - Christos Davatzikos
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Richards Building, 3700 Hamilton Walk, 7th Floor, Philadelphia, PA 19104, United States
| | | |
Collapse
|
20
|
Elliott ML. MRI-based biomarkers of accelerated aging and dementia risk in midlife: how close are we? Ageing Res Rev 2020; 61:101075. [PMID: 32325150 DOI: 10.1016/j.arr.2020.101075] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2019] [Revised: 03/10/2020] [Accepted: 04/15/2020] [Indexed: 01/18/2023]
Abstract
The global population is aging, leading to an increasing burden of age-related neurodegenerative disease. Efforts to intervene against age-related dementias in older adults have generally proven ineffective. These failures suggest that a lifetime of brain aging may be difficult to reverse once widespread deterioration has occurred. To test interventions in younger populations, biomarkers of brain aging are needed that index subtle signs of accelerated brain deterioration that are part of the putative pathway to dementia. Here I review potential MRI-based biomarkers that could connect midlife brain aging to later life dementia. I survey the literature with three questions in mind, 1) Does the biomarker index age-related changes across the lifespan? 2) Does the biomarker index cognitive ability and cognitive decline? 3) Is the biomarker sensitive to known risk factors for dementia? I find that while there is preliminary support for some midlife MRI-based biomarkers for accelerated aging, the longitudinal research that would best answer these questions is still in its infancy and needs to be further developed. I conclude with suggestions for future research.
Collapse
Affiliation(s)
- Maxwell L Elliott
- Department of Psychology and Neuroscience, Duke University, 2020 West Main Street, Suite 030, Durham, NC, 27701, USA.
| |
Collapse
|
21
|
Rallabandi VS, Tulpule K, Gattu M. Automatic classification of cognitively normal, mild cognitive impairment and Alzheimer's disease using structural MRI analysis. INFORMATICS IN MEDICINE UNLOCKED 2020. [DOI: 10.1016/j.imu.2020.100305] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
|
22
|
Haller S, Montandon ML, Rodriguez C, Garibotto V, Herrmann FR, Giannakopoulos P. Hippocampal Volume Loss, Brain Amyloid Accumulation, and APOE Status in Cognitively Intact Elderly Subjects. NEURODEGENER DIS 2019; 19:139-147. [PMID: 31846965 DOI: 10.1159/000504302] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2019] [Accepted: 10/21/2019] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Hippocampal volume loss (HVL), PET-documented brain amyloid accumulation, and APOE-ε4 status are predictive biomarkers of the transition from mild cognitive impairment to Alzheimer disease (AD). In asymptomatic cases, the role of these biomarkers remains ambiguous. In contrast to the idea that HVL occurs in late phases of neurodegeneration, recent contributions indicate that it might occur before abnormal amyloid PET occurrence in elderly subjects and that its severity could be only marginally related to APOE variants. Using a longitudinal design, we examined the determinants of HVL in our sample, i.e., brain amyloid burden and the presence of APOE-ε4, and made a longitudinal assessment of cognitive functions. METHODS We performed a 4.5-year longitudinal study on 81 elderly community dwellers (all right-handed;, 48 (59.3%) women; mean age 73.7 ± 3.7 years) including MRI at baseline and follow-up, PET amyloid during follow-up, neuropsychological assessment at 18 and 54 months, and APOE genotyping. All cases were assessed using a continuous cognitive score (CCS) that took into account the global evolution of neuropsychological performance. Linear regression models were used to identify predictors of HVL. RESULTS There was a negative association between the CCS and HVL bilaterally. In multivariate models adjusting for demographic variables, the presence of APOE-ε4 was related to increased HVL bilaterally. A trend of significance was observed with respect to the impact of amyloid positivity on HVL in the left hemisphere. No significant interaction was found between amyloid positivity and the APOE-ε4 allele. CONCLUSION The progressive decrement of neuropsychological performance is associated with HVL long before the emergence of clinically overt symptoms. In this cohort of healthy individuals, the presence of the APOE-ε4 allele was shown to be an independent predictor of worst hippocampal integrity in asymptomatic cases independently of amyloid positivity.
Collapse
Affiliation(s)
- Sven Haller
- CIRD Centre d'Imagerie Rive Droite, Geneva, Switzerland, .,Department of Surgical Sciences, Radiology, Uppsala University, Uppsala, Sweden, .,Faculty of Medicine, University of Geneva, Geneva, Switzerland,
| | - Marie-Louise Montandon
- Department of Rehabilitation and Geriatrics, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.,Department of Psychiatry, University of Geneva, Geneva, Switzerland
| | - Cristelle Rodriguez
- Department of Psychiatry, University of Geneva, Geneva, Switzerland.,Division of Institutional Measures, Medical Direction, Geneva University Hospitals, Geneva, Switzerland
| | - Valentina Garibotto
- Faculty of Medicine, University of Geneva, Geneva, Switzerland.,Division of Nuclear Medicine and Molecular Imaging, Diagnostic Department, Geneva University Hospitals, Geneva, Switzerland
| | - François R Herrmann
- Department of Rehabilitation and Geriatrics, Geneva University Hospitals and University of Geneva, Geneva, Switzerland
| | - Panteleimon Giannakopoulos
- Department of Psychiatry, University of Geneva, Geneva, Switzerland.,Division of Institutional Measures, Medical Direction, Geneva University Hospitals, Geneva, Switzerland
| |
Collapse
|
23
|
Montandon ML, Herrmann FR, Garibotto V, Rodriguez C, Haller S, Giannakopoulos P. Determinants of mesial temporal lobe volume loss in older individuals with preserved cognition: a longitudinal PET amyloid study. Neurobiol Aging 2019; 87:108-114. [PMID: 32057528 DOI: 10.1016/j.neurobiolaging.2019.12.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2019] [Revised: 12/03/2019] [Accepted: 12/05/2019] [Indexed: 12/11/2022]
Abstract
Mesial temporal lobe (MTL) is prominently affected in normal aging and associated with neurodegeneration in AD. Whether or not MTL atrophy is dependent on increasing amyloid load before the emergence of cognitive deficits is still disputed. We performed a 4.5-year longitudinal study in 75 older community dwellers (48 women, mean age: 79.3 years) including magnetic resonance imaging at baseline and follow-up, positron emission tomography amyloid during follow-up, neuropsychological assessment at 18 and 55 months, and APOE genotyping. Linear regression models were used to identify predictors of the MTL volume loss. Amyloid load was negatively associated with bilateral MTL volume at baseline explaining almost 10.5% of its variability. In multivariate models including time of follow-up and demographic variables (older age, male gender), this percentage exceeded 35%. The APOE4 allele independently contributed another 6%. Cognitive changes had a modest but still significant negative association with MTL volume loss. Our data support a multifactorial model including amyloid deposition, older age, male gender, APOE4 allele, and slight decline of cognitive abilities as independent predictors of MTL volume loss in brain aging.
Collapse
Affiliation(s)
- Marie-Louise Montandon
- Department of Rehabilitation and Geriatrics, Geneva University Hospitals and University of Geneva, Thônex, Switzerland; Department of Psychiatry, University of Geneva, Thônex, Switzerland
| | - François R Herrmann
- Department of Rehabilitation and Geriatrics, Geneva University Hospitals and University of Geneva, Thônex, Switzerland.
| | - Valentina Garibotto
- Division of Nuclear Medicine and Molecular Imaging, Diagnostic Department, Geneva University Hospitals and University of Geneva, Geneva, Switzerland
| | - Cristelle Rodriguez
- Department of Psychiatry, University of Geneva, Thônex, Switzerland; Medical Direction, University of Geneva Hospitals, Geneva, Switzerland
| | - Sven Haller
- CIRD - Centre d'Imagerie Rive Droite, Geneva, Switzerland; Department of Surgical Sciences, Radiology, Uppsala University, Uppsala, Sweden; Department of Neuroradiology, Faculty of Medicine of the University of Geneva, Geneva, Switzerland
| | - Panteleimon Giannakopoulos
- Department of Psychiatry, University of Geneva, Thônex, Switzerland; Medical Direction, University of Geneva Hospitals, Geneva, Switzerland
| |
Collapse
|
24
|
Abstract
Radiogenomics, defined as the integrated analysis of radiologic imaging and genetic data, is a well-established tool shown to augment neuroimaging in the clinical diagnosis, prognostication, and scientific study of late-onset Alzheimer disease (LOAD). Early work using candidate single nucleotide polymorphisms (SNPs) identified genetic variation in APOE, BIN1, CLU, and CR1 as key modifiers of brain structure and function using magnetic resonance imaging (MRI). More recently, polygenic risk scores used in conjunction with MRI and positron emission tomography have shown great promise as a risk-stratification tool for clinical trials and care-management decisions. In addition, recent work using multimodal MRI and positron emission tomography as proxies of LOAD progression has identified novel risk variants that are enhancing our understanding of LOAD pathophysiology and progression. Herein, we highlight key studies and trends in the radiogenomics of LOAD over the past two decades and their implications for clinical practice and scientific research.
Collapse
|
25
|
Sampedro F, Marín-Lahoz J, Martínez-Horta S, Pagonabarraga J, Kulisevsky J. Pattern of cortical thinning associated with the BDNF Val66Met polymorphism in Parkinson's disease. Behav Brain Res 2019; 372:112039. [PMID: 31202861 DOI: 10.1016/j.bbr.2019.112039] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2019] [Revised: 05/27/2019] [Accepted: 06/12/2019] [Indexed: 11/16/2022]
Abstract
The brain-derived neurotrophic factor (BDNF) val66met polymorphism has been suggested to modulate cognitive deterioration in Parkinson's disease (PD). In particular, the val/val genotype has been recently suggested to increase the risk of cognitive decline in this population. However, to date, little is known about the underlying brain alterations responsible for this association. Here, in a cohort of 93 early PD patients with preserved cognition from the Parkinson's Progression Markers Initiative (PPMI), we found that BDNF val/val patients experience an increased cortical atrophy rate with respect to met carriers in frontal and posterior-cortical regions (p<0.05, corrected). Additionally, BDNF val/val PD patients showed lower I123-ioflupane SPECT DAT uptake in the contralateral caudate region (p=0.017) than met carriers, suggesting an increased striatal dopaminergic degeneration, which represents the pathological hallmark of PD. None of these observations were found in a sample of 38 healthy control (HC) subjects of comparable age and gender. We also observed an interaction effect on brain structure between the BDNF and APOE genotypes: cortical atrophy was associated with harboring the apoliprotein E (APOE) ε4 allele only in BDNF val/met subjects (both in HC and PD groups). Overall, these findings suggest that harboring the BDNF val/val genotype in PD leads to a set of cortical and subcortical brain alterations that could promote cognitive decline in this population.
Collapse
Affiliation(s)
- Frederic Sampedro
- Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Biomedical Research Institute (IIB-Sant Pau), Barcelona, Spain; Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Spain
| | - Juan Marín-Lahoz
- Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Biomedical Research Institute (IIB-Sant Pau), Barcelona, Spain; Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Spain
| | - Saul Martínez-Horta
- Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Biomedical Research Institute (IIB-Sant Pau), Barcelona, Spain; Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Spain
| | - Javier Pagonabarraga
- Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Biomedical Research Institute (IIB-Sant Pau), Barcelona, Spain; Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Spain
| | - Jaime Kulisevsky
- Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Biomedical Research Institute (IIB-Sant Pau), Barcelona, Spain; Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Spain.
| |
Collapse
|
26
|
The Contribution of Genetic Factors to Cognitive Impairment and Dementia: Apolipoprotein E Gene, Gene Interactions, and Polygenic Risk. Int J Mol Sci 2019; 20:ijms20051177. [PMID: 30866553 PMCID: PMC6429136 DOI: 10.3390/ijms20051177] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2019] [Accepted: 02/26/2019] [Indexed: 12/19/2022] Open
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disease. Although it has been studied for years, the pathogenesis of AD is still controversial. Genetic factors may play an important role in pathogenesis, with the apolipoprotein E (APOE) gene among the greatest risk factors for AD. In this review, we focus on the influence of genetic factors, including the APOE gene, the interaction between APOE and other genes, and the polygenic risk factors for cognitive function and dementia. The presence of the APOE ε4 allele is associated with increased AD risk and reduced age of AD onset. Accelerated cognitive decline and abnormal internal environment, structure, and function of the brain were also found in ε4 carriers. The effect of the APOE promoter on cognition and the brain was confirmed by some studies, but further investigation is still needed. We also describe the effects of the associations between APOE and other genetic risk factors on cognition and the brain that exhibit a complex gene⁻gene interaction, and we consider the importance of using a polygenic risk score to investigate the association between genetic variance and phenotype.
Collapse
|
27
|
Squarzoni P, Duran FLS, Busatto GF, Alves TCTDF. Reduced Gray Matter Volume of the Thalamus and Hippocampal Region in Elderly Healthy Adults with no Impact of APOE ɛ4: A Longitudinal Voxel-Based Morphometry Study. J Alzheimers Dis 2019; 62:757-771. [PMID: 29480170 DOI: 10.3233/jad-161036] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
BACKGROUND Many cross-sectional voxel-based morphometry (VBM) investigations have shown significant inverse correlations between chronological age and gray matter (GM) volume in several brain regions in healthy humans. However, few VBM studies have documented GM decrements in the healthy elderly with repeated MRI measurements obtained in the same subjects. Also, the extent to which the APOE ɛ4 allele influences longitudinal findings of GM reduction in the healthy elderly is unclear. OBJECTIVE Verify whether regional GM changes are associated with significant decrements in cognitive performance taking in account the presence of the APOE ɛ4 allele. METHODS Using structural MRI datasets acquired in 55 cognitively intact elderly subjects at two time-points separated by approximately three years, we searched for voxels showing significant GM reductions taking into account differences in APOE genotype. RESULTS We found global GM reductions as well as regional GM decrements in the right thalamus and left parahippocampal gyrus (p < 0.05, family-wise error corrected for multiple comparisons over the whole brain). These findings were not affected by APOE ɛ4. CONCLUSIONS Irrespective of APOE ɛ4, longitudinal VBM analyses show that the hippocampal region and thalamus are critical sites where GM shrinkage is greater than the degree of global volume reduction in healthy elderly subjects.
Collapse
Affiliation(s)
- Paula Squarzoni
- Department of Psychiatry, Laboratory of Psychiatric Neuroimaging (LIM 21), Faculty of Medicine, University of São Paulo, São Paulo, Brazil.,Núcleo de Apoio à Pesquisa em Neurociência Aplicada (NAPNA), University of São Paulo, São Paulo, Brazil
| | - Fabio Luis Souza Duran
- Department of Psychiatry, Laboratory of Psychiatric Neuroimaging (LIM 21), Faculty of Medicine, University of São Paulo, São Paulo, Brazil.,Núcleo de Apoio à Pesquisa em Neurociência Aplicada (NAPNA), University of São Paulo, São Paulo, Brazil
| | - Geraldo F Busatto
- Department of Psychiatry, Laboratory of Psychiatric Neuroimaging (LIM 21), Faculty of Medicine, University of São Paulo, São Paulo, Brazil.,Núcleo de Apoio à Pesquisa em Neurociência Aplicada (NAPNA), University of São Paulo, São Paulo, Brazil
| | - Tania Correa Toledo de Ferraz Alves
- Department of Psychiatry, Laboratory of Psychiatric Neuroimaging (LIM 21), Faculty of Medicine, University of São Paulo, São Paulo, Brazil.,Núcleo de Apoio à Pesquisa em Neurociência Aplicada (NAPNA), University of São Paulo, São Paulo, Brazil
| |
Collapse
|
28
|
Bussy A, Snider BJ, Coble D, Xiong C, Fagan AM, Cruchaga C, Benzinger TLS, Gordon BA, Hassenstab J, Bateman RJ, Morris JC. Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network. Neurobiol Aging 2018; 75:42-50. [PMID: 30530186 DOI: 10.1016/j.neurobiolaging.2018.10.011] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2018] [Revised: 09/28/2018] [Accepted: 10/05/2018] [Indexed: 11/19/2022]
Abstract
The apolipoprotein E ε4 allele (APOE4) is the major genetic risk factor for sporadic Alzheimer's disease (AD). APOE4 may have effects on cognition and brain atrophy years before the onset of symptomatic AD. We analyzed the effects of APOE4 in a unique cohort of young adults who had undergone comprehensive assessments as part of the Dominantly Inherited Alzheimer Network (DIAN), an international longitudinal study of individuals from families with autosomal dominant AD. We analyzed the effect of an APOE4 allele on cognitive measures, volumetric MRI, amyloid deposition, glucose metabolism, and on cerebrospinal fluid levels of AD biomarkers in 162 participants that did not carry the mutant gene (noncarriers). APOE4+ and APOE4- mutation noncarriers had similar performance on cognitive measures. Amyloid deposition began at an earlier age in APOE4+ participants, whereas hippocampal volume was similar between the groups. These preliminary findings are consistent with growing evidence that the APOE4 allele may exert effects in midlife years before symptom onset, promoting amyloid deposition before altering cognitive performance or brain structure.
Collapse
Affiliation(s)
- Aurélie Bussy
- Knight Alzheimer Disease Research Center, Washington University School of Medicine, Saint Louis, MO; Department of Neurology, Washington University School of Medicine, Saint Louis, MO
| | - B Joy Snider
- Knight Alzheimer Disease Research Center, Washington University School of Medicine, Saint Louis, MO; Department of Neurology, Washington University School of Medicine, Saint Louis, MO.
| | - Dean Coble
- Knight Alzheimer Disease Research Center, Washington University School of Medicine, Saint Louis, MO; Division of Biostatistics, Washington University School of Medicine, Saint Louis, MO
| | - Chengjie Xiong
- Knight Alzheimer Disease Research Center, Washington University School of Medicine, Saint Louis, MO; Division of Biostatistics, Washington University School of Medicine, Saint Louis, MO
| | - Anne M Fagan
- Knight Alzheimer Disease Research Center, Washington University School of Medicine, Saint Louis, MO; Department of Neurology, Washington University School of Medicine, Saint Louis, MO
| | - Carlos Cruchaga
- Knight Alzheimer Disease Research Center, Washington University School of Medicine, Saint Louis, MO; Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO
| | - Tammie L S Benzinger
- Knight Alzheimer Disease Research Center, Washington University School of Medicine, Saint Louis, MO; Department of Radiology, Washington University School of Medicine, Saint Louis, MO
| | - Brian A Gordon
- Knight Alzheimer Disease Research Center, Washington University School of Medicine, Saint Louis, MO; Department of Radiology, Washington University School of Medicine, Saint Louis, MO
| | - Jason Hassenstab
- Knight Alzheimer Disease Research Center, Washington University School of Medicine, Saint Louis, MO; Department of Neurology, Washington University School of Medicine, Saint Louis, MO
| | - Randall J Bateman
- Knight Alzheimer Disease Research Center, Washington University School of Medicine, Saint Louis, MO; Department of Neurology, Washington University School of Medicine, Saint Louis, MO
| | - John C Morris
- Knight Alzheimer Disease Research Center, Washington University School of Medicine, Saint Louis, MO; Department of Neurology, Washington University School of Medicine, Saint Louis, MO
| |
Collapse
|
29
|
Habes M, Sotiras A, Erus G, Toledo JB, Janowitz D, Wolk DA, Shou H, Bryan NR, Doshi J, Völzke H, Schminke U, Hoffmann W, Resnick SM, Grabe HJ, Davatzikos C. White matter lesions: Spatial heterogeneity, links to risk factors, cognition, genetics, and atrophy. Neurology 2018; 91:e964-e975. [PMID: 30076276 DOI: 10.1212/wnl.0000000000006116] [Citation(s) in RCA: 90] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2017] [Accepted: 06/04/2018] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVES To investigate spatial heterogeneity of white matter lesions or hyperintensities (WMH). METHODS MRI scans of 1,836 participants (median age 52.2 ± 13.16 years) encompassing a wide age range (22-84 years) from the cross-sectional Study of Health in Pomerania (Germany) were included as discovery set identifying spatially distinct components of WMH using a structural covariance approach. Scans of 307 participants (median age 73.8 ± 10.2 years, with 747 observations) from the Baltimore Longitudinal Study of Aging (United States) were included to examine differences in longitudinal progression of these components. The associations of these components with vascular risk factors, cortical atrophy, Alzheimer disease (AD) genetics, and cognition were then investigated using linear regression. RESULTS WMH were found to occur nonuniformly, with higher frequency within spatially heterogeneous patterns encoded by 4 components, which were consistent with common categorizations of deep and periventricular WMH, while further dividing the latter into posterior, frontal, and dorsal components. Temporal trends of the components differed both cross-sectionally and longitudinally. Frontal periventricular WMH were most distinctive as they appeared in the fifth decade of life, whereas the other components appeared later in life during the sixth decade. Furthermore, frontal WMH were associated with systolic blood pressure and with pronounced atrophy including AD-related regions. AD polygenic risk score was associated with the dorsal periventricular component in the elderly. Cognitive decline was associated with the dorsal component. CONCLUSIONS These results support the hypothesis that the appearance of WMH follows age and disease-dependent regional distribution patterns, potentially influenced by differential underlying pathophysiologic mechanisms, and possibly with a differential link to vascular and neurodegenerative changes.
Collapse
Affiliation(s)
- Mohamad Habes
- From the Center for Biomedical Image Computing and Analytics (M.H., A.S., G.E., N.R.B., J.D., C.D.), Department of Neurology and Penn Memory Center (M.H., D.A.W.), and Department of Biostatistics and Epidemiology (H.S.), University of Pennsylvania, Philadelphia; Department of Psychiatry (M.H., D.J., H.J.G.), Institute for Community Medicine (M.H., H.V., W.H.), and Department of Neurology (U.S.), University of Greifswald, Germany; Department of Neurology (J.B.T.), Houston Methodist Hospital, TX; German Center for Neurodegenerative Diseases (W.H., H.J.G.), Rostock/Greifswald, Germany; and Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD.
| | - Aristeidis Sotiras
- From the Center for Biomedical Image Computing and Analytics (M.H., A.S., G.E., N.R.B., J.D., C.D.), Department of Neurology and Penn Memory Center (M.H., D.A.W.), and Department of Biostatistics and Epidemiology (H.S.), University of Pennsylvania, Philadelphia; Department of Psychiatry (M.H., D.J., H.J.G.), Institute for Community Medicine (M.H., H.V., W.H.), and Department of Neurology (U.S.), University of Greifswald, Germany; Department of Neurology (J.B.T.), Houston Methodist Hospital, TX; German Center for Neurodegenerative Diseases (W.H., H.J.G.), Rostock/Greifswald, Germany; and Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD
| | - Guray Erus
- From the Center for Biomedical Image Computing and Analytics (M.H., A.S., G.E., N.R.B., J.D., C.D.), Department of Neurology and Penn Memory Center (M.H., D.A.W.), and Department of Biostatistics and Epidemiology (H.S.), University of Pennsylvania, Philadelphia; Department of Psychiatry (M.H., D.J., H.J.G.), Institute for Community Medicine (M.H., H.V., W.H.), and Department of Neurology (U.S.), University of Greifswald, Germany; Department of Neurology (J.B.T.), Houston Methodist Hospital, TX; German Center for Neurodegenerative Diseases (W.H., H.J.G.), Rostock/Greifswald, Germany; and Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD
| | - Jon B Toledo
- From the Center for Biomedical Image Computing and Analytics (M.H., A.S., G.E., N.R.B., J.D., C.D.), Department of Neurology and Penn Memory Center (M.H., D.A.W.), and Department of Biostatistics and Epidemiology (H.S.), University of Pennsylvania, Philadelphia; Department of Psychiatry (M.H., D.J., H.J.G.), Institute for Community Medicine (M.H., H.V., W.H.), and Department of Neurology (U.S.), University of Greifswald, Germany; Department of Neurology (J.B.T.), Houston Methodist Hospital, TX; German Center for Neurodegenerative Diseases (W.H., H.J.G.), Rostock/Greifswald, Germany; and Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD
| | - Deborah Janowitz
- From the Center for Biomedical Image Computing and Analytics (M.H., A.S., G.E., N.R.B., J.D., C.D.), Department of Neurology and Penn Memory Center (M.H., D.A.W.), and Department of Biostatistics and Epidemiology (H.S.), University of Pennsylvania, Philadelphia; Department of Psychiatry (M.H., D.J., H.J.G.), Institute for Community Medicine (M.H., H.V., W.H.), and Department of Neurology (U.S.), University of Greifswald, Germany; Department of Neurology (J.B.T.), Houston Methodist Hospital, TX; German Center for Neurodegenerative Diseases (W.H., H.J.G.), Rostock/Greifswald, Germany; and Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD
| | - David A Wolk
- From the Center for Biomedical Image Computing and Analytics (M.H., A.S., G.E., N.R.B., J.D., C.D.), Department of Neurology and Penn Memory Center (M.H., D.A.W.), and Department of Biostatistics and Epidemiology (H.S.), University of Pennsylvania, Philadelphia; Department of Psychiatry (M.H., D.J., H.J.G.), Institute for Community Medicine (M.H., H.V., W.H.), and Department of Neurology (U.S.), University of Greifswald, Germany; Department of Neurology (J.B.T.), Houston Methodist Hospital, TX; German Center for Neurodegenerative Diseases (W.H., H.J.G.), Rostock/Greifswald, Germany; and Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD
| | - Haochang Shou
- From the Center for Biomedical Image Computing and Analytics (M.H., A.S., G.E., N.R.B., J.D., C.D.), Department of Neurology and Penn Memory Center (M.H., D.A.W.), and Department of Biostatistics and Epidemiology (H.S.), University of Pennsylvania, Philadelphia; Department of Psychiatry (M.H., D.J., H.J.G.), Institute for Community Medicine (M.H., H.V., W.H.), and Department of Neurology (U.S.), University of Greifswald, Germany; Department of Neurology (J.B.T.), Houston Methodist Hospital, TX; German Center for Neurodegenerative Diseases (W.H., H.J.G.), Rostock/Greifswald, Germany; and Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD
| | - Nick R Bryan
- From the Center for Biomedical Image Computing and Analytics (M.H., A.S., G.E., N.R.B., J.D., C.D.), Department of Neurology and Penn Memory Center (M.H., D.A.W.), and Department of Biostatistics and Epidemiology (H.S.), University of Pennsylvania, Philadelphia; Department of Psychiatry (M.H., D.J., H.J.G.), Institute for Community Medicine (M.H., H.V., W.H.), and Department of Neurology (U.S.), University of Greifswald, Germany; Department of Neurology (J.B.T.), Houston Methodist Hospital, TX; German Center for Neurodegenerative Diseases (W.H., H.J.G.), Rostock/Greifswald, Germany; and Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD
| | - Jimit Doshi
- From the Center for Biomedical Image Computing and Analytics (M.H., A.S., G.E., N.R.B., J.D., C.D.), Department of Neurology and Penn Memory Center (M.H., D.A.W.), and Department of Biostatistics and Epidemiology (H.S.), University of Pennsylvania, Philadelphia; Department of Psychiatry (M.H., D.J., H.J.G.), Institute for Community Medicine (M.H., H.V., W.H.), and Department of Neurology (U.S.), University of Greifswald, Germany; Department of Neurology (J.B.T.), Houston Methodist Hospital, TX; German Center for Neurodegenerative Diseases (W.H., H.J.G.), Rostock/Greifswald, Germany; and Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD
| | - Henry Völzke
- From the Center for Biomedical Image Computing and Analytics (M.H., A.S., G.E., N.R.B., J.D., C.D.), Department of Neurology and Penn Memory Center (M.H., D.A.W.), and Department of Biostatistics and Epidemiology (H.S.), University of Pennsylvania, Philadelphia; Department of Psychiatry (M.H., D.J., H.J.G.), Institute for Community Medicine (M.H., H.V., W.H.), and Department of Neurology (U.S.), University of Greifswald, Germany; Department of Neurology (J.B.T.), Houston Methodist Hospital, TX; German Center for Neurodegenerative Diseases (W.H., H.J.G.), Rostock/Greifswald, Germany; and Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD
| | - Ulf Schminke
- From the Center for Biomedical Image Computing and Analytics (M.H., A.S., G.E., N.R.B., J.D., C.D.), Department of Neurology and Penn Memory Center (M.H., D.A.W.), and Department of Biostatistics and Epidemiology (H.S.), University of Pennsylvania, Philadelphia; Department of Psychiatry (M.H., D.J., H.J.G.), Institute for Community Medicine (M.H., H.V., W.H.), and Department of Neurology (U.S.), University of Greifswald, Germany; Department of Neurology (J.B.T.), Houston Methodist Hospital, TX; German Center for Neurodegenerative Diseases (W.H., H.J.G.), Rostock/Greifswald, Germany; and Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD
| | - Wolfgang Hoffmann
- From the Center for Biomedical Image Computing and Analytics (M.H., A.S., G.E., N.R.B., J.D., C.D.), Department of Neurology and Penn Memory Center (M.H., D.A.W.), and Department of Biostatistics and Epidemiology (H.S.), University of Pennsylvania, Philadelphia; Department of Psychiatry (M.H., D.J., H.J.G.), Institute for Community Medicine (M.H., H.V., W.H.), and Department of Neurology (U.S.), University of Greifswald, Germany; Department of Neurology (J.B.T.), Houston Methodist Hospital, TX; German Center for Neurodegenerative Diseases (W.H., H.J.G.), Rostock/Greifswald, Germany; and Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD
| | - Susan M Resnick
- From the Center for Biomedical Image Computing and Analytics (M.H., A.S., G.E., N.R.B., J.D., C.D.), Department of Neurology and Penn Memory Center (M.H., D.A.W.), and Department of Biostatistics and Epidemiology (H.S.), University of Pennsylvania, Philadelphia; Department of Psychiatry (M.H., D.J., H.J.G.), Institute for Community Medicine (M.H., H.V., W.H.), and Department of Neurology (U.S.), University of Greifswald, Germany; Department of Neurology (J.B.T.), Houston Methodist Hospital, TX; German Center for Neurodegenerative Diseases (W.H., H.J.G.), Rostock/Greifswald, Germany; and Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD
| | - Hans J Grabe
- From the Center for Biomedical Image Computing and Analytics (M.H., A.S., G.E., N.R.B., J.D., C.D.), Department of Neurology and Penn Memory Center (M.H., D.A.W.), and Department of Biostatistics and Epidemiology (H.S.), University of Pennsylvania, Philadelphia; Department of Psychiatry (M.H., D.J., H.J.G.), Institute for Community Medicine (M.H., H.V., W.H.), and Department of Neurology (U.S.), University of Greifswald, Germany; Department of Neurology (J.B.T.), Houston Methodist Hospital, TX; German Center for Neurodegenerative Diseases (W.H., H.J.G.), Rostock/Greifswald, Germany; and Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD
| | - Christos Davatzikos
- From the Center for Biomedical Image Computing and Analytics (M.H., A.S., G.E., N.R.B., J.D., C.D.), Department of Neurology and Penn Memory Center (M.H., D.A.W.), and Department of Biostatistics and Epidemiology (H.S.), University of Pennsylvania, Philadelphia; Department of Psychiatry (M.H., D.J., H.J.G.), Institute for Community Medicine (M.H., H.V., W.H.), and Department of Neurology (U.S.), University of Greifswald, Germany; Department of Neurology (J.B.T.), Houston Methodist Hospital, TX; German Center for Neurodegenerative Diseases (W.H., H.J.G.), Rostock/Greifswald, Germany; and Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD
| |
Collapse
|
30
|
Rathore S, Habes M, Iftikhar MA, Shacklett A, Davatzikos C. A review on neuroimaging-based classification studies and associated feature extraction methods for Alzheimer's disease and its prodromal stages. Neuroimage 2017; 155:530-548. [PMID: 28414186 PMCID: PMC5511557 DOI: 10.1016/j.neuroimage.2017.03.057] [Citation(s) in RCA: 298] [Impact Index Per Article: 42.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2016] [Revised: 03/25/2017] [Accepted: 03/28/2017] [Indexed: 01/18/2023] Open
Abstract
Neuroimaging has made it possible to measure pathological brain changes associated with Alzheimer's disease (AD) in vivo. Over the past decade, these measures have been increasingly integrated into imaging signatures of AD by means of classification frameworks, offering promising tools for individualized diagnosis and prognosis. We reviewed neuroimaging-based studies for AD and mild cognitive impairment classification, selected after online database searches in Google Scholar and PubMed (January, 1985-June, 2016). We categorized these studies based on the following neuroimaging modalities (and sub-categorized based on features extracted as a post-processing step from these modalities): i) structural magnetic resonance imaging [MRI] (tissue density, cortical surface, and hippocampal measurements), ii) functional MRI (functional coherence of different brain regions, and the strength of the functional connectivity), iii) diffusion tensor imaging (patterns along the white matter fibers), iv) fluorodeoxyglucose positron emission tomography (FDG-PET) (metabolic rate of cerebral glucose), and v) amyloid-PET (amyloid burden). The studies reviewed indicate that the classification frameworks formulated on the basis of these features show promise for individualized diagnosis and prediction of clinical progression. Finally, we provided a detailed account of AD classification challenges and addressed some future research directions.
Collapse
Affiliation(s)
- Saima Rathore
- Center for Biomedical Image Computing and Analytics, Perelman School of Medicine, University of Pennsylvania, USA
| | - Mohamad Habes
- Center for Biomedical Image Computing and Analytics, Perelman School of Medicine, University of Pennsylvania, USA
| | - Muhammad Aksam Iftikhar
- Department of Computer Science, Comsats Institute of Information technology, Lahore, Pakistan
| | - Amanda Shacklett
- Center for Biomedical Image Computing and Analytics, Perelman School of Medicine, University of Pennsylvania, USA
| | - Christos Davatzikos
- Center for Biomedical Image Computing and Analytics, Perelman School of Medicine, University of Pennsylvania, USA.
| |
Collapse
|
31
|
Haller S, Montandon ML, Rodriguez C, Ackermann M, Herrmann FR, Giannakopoulos P. APOE* E4 Is Associated with Gray Matter Loss in the Posterior Cingulate Cortex in Healthy Elderly Controls Subsequently Developing Subtle Cognitive Decline. AJNR Am J Neuroradiol 2017; 38:1335-1342. [PMID: 28495939 DOI: 10.3174/ajnr.a5184] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2016] [Accepted: 02/17/2017] [Indexed: 12/11/2022]
Abstract
BACKGROUND AND PURPOSE The presence of apolipoprotein E4 (APOE*E4) is the strongest currently known genetic risk factor for Alzheimer disease and is associated with brain gray matter loss, notably in areas involved in Alzheimer disease pathology. Our objective was to assess the effect of APOE*E4 on brain structures in healthy elderly controls who subsequently developed subtle cognitive decline. MATERIALS AND METHODS This prospective study included 382 community-dwelling elderly controls. At baseline, participants underwent MR imaging at 3T, extensive neuropsychological testing, and genotyping. After neuropsychological follow-up at 18 months, participants were classified into cognitively stable controls and cognitively deteriorating controls. Data analysis included whole-brain voxel-based morphometry and ROI analysis of GM. RESULTS APOE*E4-related GM loss at baseline was found only in the cognitively deteriorating controls in the posterior cingulate cortex. There was no APOE*E4-related effect in the hippocampus, mesial temporal lobe, or brain areas not involved in Alzheimer disease pathology. Controls in the cognitively deteriorating group had slightly lower GM concentration in the hippocampus at baseline. Higher GM densities in the hippocampus, middle temporal lobe, and amygdala were associated with a decreased risk for cognitively deteriorating group status at follow-up. CONCLUSIONS APOE*E4-related GM loss in the posterior cingulate cortex (an area involved in Alzheimer disease pathology) was found only in those elderly controls who subsequently developed subtle cognitive decline but not in cognitively stable controls. This finding might explain the partially conflicting results of previous studies that typically did not include detailed neuropsychological assessment and follow-up. Most important, APOE*E4 status had no impact on GM density in areas affected early by neurofibrillary tangle formation such as the hippocampus and mesial temporal lobe.
Collapse
Affiliation(s)
- S Haller
- From the Affidea Centre de Diagnostic Radiologique de Carouge (S.H.), Geneva, Switzerland .,Faculty of Medicine (S.H., M.-L.M., F.R.H., P.G.), University of Geneva, Switzerland.,Departments of Surgical Sciences and Radiology (S.H.), Uppsala University, Uppsala, Sweden.,Department of Neuroradiology (S.H.), University Hospital Freiburg, Freiburg, Germany
| | - M-L Montandon
- Faculty of Medicine (S.H., M.-L.M., F.R.H., P.G.), University of Geneva, Switzerland.,Department of Mental Health and Psychiatry (M.-L.M., M.A.)
| | - C Rodriguez
- Division of Institutional Measures, Medical Direction (C.R., P.G.)
| | - M Ackermann
- Department of Mental Health and Psychiatry (M.-L.M., M.A.)
| | - F R Herrmann
- Faculty of Medicine (S.H., M.-L.M., F.R.H., P.G.), University of Geneva, Switzerland.,Division of Geriatrics, Department of Internal Medicine, Rehabilitation and Geriatrics (F.R.H.), University Hospitals of Geneva, Geneva, Switzerland
| | - P Giannakopoulos
- Faculty of Medicine (S.H., M.-L.M., F.R.H., P.G.), University of Geneva, Switzerland.,Division of Institutional Measures, Medical Direction (C.R., P.G.)
| |
Collapse
|